TNFRSF1B and neoplasm: TNFR2-PLGA-ADR nanoparticle treatment resulted in the death of 26.38% of CT26 tumor cells and 29.59% of MC38 tumor cells (including early apoptosis, e.g., Annexin V+7AAD− cells, and late apoptosis, e.g., Annexin V+7ADD+ cells), which was markedly higher than tumor cells treated with ISO-PLGA-ADR (20.15% and 24.54%, respectively; P < 0.01 to 0.05; Fig. S3).